Dysregulation of Iron and Ranal Anemia Treatment in patients with chronic kidney disease

Dysregulation of Iron and Ranal Anemia Treatment in patients with chronic kidney disease - DIRAT study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006833

Enrollment

250

Registered

2012-01-01

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

ESAs is changed to long-acting ESAs as renal anemia treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic kidney disease patients with hyporesponsive anemia

Exclusion criteria

Exclusion criteria: Bleeding of gastrointestinal tract, malignant disease, severe infection

Design outcomes

Primary

Measure	Time frame
Anemia: RBC, Hb, Ht, reticulocytes etc. Iron regulation: serum iron, TIBC, trasnferrin saturation rate, ferritin, soluble transferrin receptor, hepcidin, iron transporter, aminolevulinic acid etc.	—

Countries

Japan

Contacts

Public ContactYukiko Hasuike

Hyogo College of Medicine Division of Kidney and Dialysis, Department of Internal Medicine

cherry39@hyo-med.ac.jp0798-45-6521

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026